Form 4: MAIA Biotechnology Director Acquires Stock Options

Director Jean-Manasse Theagene acquired 20,291 stock options in MAIA Biotechnology, Inc. on April 4, 2025.

Summary

• Jean-Manasse Theagene, a director of MAIA Biotechnology, Inc., filed a Form 4 on April 8, 2025, reporting a transaction.
• The transaction involved the acquisition of 20,291 stock options on April 4, 2025.
• These options, with an exercise price of $1.5, vest immediately and expire on April 4, 2035.
• The options are granted under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan and represent the right to buy shares of common stock.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of options by a director could be interpreted as a mildly positive signal.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

MAIA Biotechnology, stock options, Form 4, director, equity incentive plan, Theagene, acquisition